CRMD — CorMedix Inc.

CRMD Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $104.3 million, a year-over-year increase of $77.5 million.
  • DefenCath Sales: $88.8 million.
  • Melinta Contribution: Approximately $15.5 million (one month of operations).
• Net Income: $108.6 million ($1.26 per diluted share), significantly improved from a loss of $2.8 million in Q3 2024.
• Adjusted EBITDA: $71.8 million, up from a loss of $2 million in the same quarter last year.
• Operating Expenses: Increased to $42.6 million from $14.1 million, driven by acquisition-related costs and increased R&D investments.
• Cash Position: Ended the quarter with $55.7 million in cash and equivalents, with expectations to reach approximately $100 million by year-end.

2. Strategic Updates and Business Highlights

• Acquisition of Melinta Therapeutics: Closed on August 29, 2025, viewed as transformative, creating a diversified specialty pharmaceutical company. Integration is progressing well, with expected synergies of $30 million by year-end.
• Rebranding: CorMedix is rebranding to CorMedix Therapeutics to reflect its expanded portfolio and commitment to novel therapies.
• Clinical Developments:
  • DefenCath: Continued utilization growth in outpatient hemodialysis; planning for post-TDAPA periods starting July 2026.
  • Rezzayo: Phase III study results expected in Q2 2026 for prophylaxis against invasive fungal infections, targeting a $2 billion market.
  • New Indications: Expansion of DefenCath into preventing CLABSI in TPN patients, with a potential market of $750 million.

3. Forward Guidance and Outlook

• Revenue Guidance: Raised full-year pro forma combined revenue guidance to $390 million - $410 million.
• Adjusted EBITDA Guidance: Increased to $220 million - $240 million for 2025.
• Q4 Revenue Expectations: Projected between $115 million and $135 million, reflecting continued momentum from DefenCath and a full quarter contribution from Melinta.

4. Challenges and Points of Concern

• Pricing Dynamics: Anticipated price compression post-TDAPA due to regulatory changes, with uncertainty around the final ESRD rule affecting revenue in the second half of 2026.
• Integration Risks: While integration is progressing, the transition to a unified sales organization may present challenges.
• Legislative Risks: Potential changes to TDAPA reimbursement could impact future revenue, with ongoing legislative discussions that may affect pricing structures.

5. Notable Q&A Insights

• DefenCath Utilization: Utilization is reportedly higher than expected, with inventory levels indicating strong demand. However, specific patient numbers were not disclosed.
• Real-World Evidence Study: Expected to provide data on CRBSI reduction and hospitalizations from 2,000 patients, with results anticipated in the coming weeks.
• Post-TDAPA Strategy: Emphasis on engaging with Medicare Advantage payers to expand market share, as the majority of current users are Medicare fee-for-service patients.
• Market Perception of Melinta: Management believes the value of the Melinta acquisition is underestimated, particularly regarding its stable revenue base and the potential of Rezzayo as a significant growth driver.

This summary encapsulates the key points from the earnings call, highlighting both the achievements and the challenges faced by CorMedix as it navigates its growth trajectory.